Anti-Human VTCN1/B7-H4 Reference Antibody (AZD8205)

Description: Anti-Human VTCN1/B7-H4 (AZD8205) (BS10972) is a research-grade recombinant antibody targeting V-set domain-containing T-cell activation inhibitor 1. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: V-setdomain-containingT-cellactivationinhibitor1,B7h.5,B7homolog4,B7-H4,T-cellcostimulatorymoleculeB7x,B7H4,VTCN1,ProteinB7S1,ImmunecostimulatoryproteinB7-H4
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: AZD8205
Background: V-set domain-containing T-cell activation inhibitor 1 (VTCN1/B7-H4) is a ~30 kDa protein. Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation.
Note: For research use only. Not suitable for clinical or therapeutic use.